Bal Pharma

Bal Pharma Working Capital

The Working Capital of Bal Pharma (BALPHARMA.NS) as of Nov 3, 2026 is -817.93 M INR. In the previous year, Working Capital was 46.90 M INR — a change of -1,843.87% (lower).

Working Capital

-817.93 MINR

YoY

-1,843.87%

Last updated:

Working Capital of Bal Pharma is 2026 -817.93 M INR. Working Capital of Bal Pharma was 2025 46.90 M INR. It decreases by -1,843.87% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bal Pharma Stock analysis

What does Bal Pharma do? Bal Pharma Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company specializes in bulk actives, prescription drugs, generics, and pharma intermediates, targeting therapeutic areas such as anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. Its product portfolio includes APIs like antihistamine, platelet inhibitor, anti-diabetic, and anti-inflammatory agents, alongside finished formulations in tablets, capsules, syrups, and ointments. Key brands such as ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP are marketed to healthcare providers and consumers in these therapeutic segments. The company sells its APIs to other pharmaceutical manufacturers for further processing into finished products, while its finished formulations are distributed to hospitals, pharmacies, and clinics. Brands like AYURFINE and MENOLEAP CAPSULES target specific patient groups, such as those requiring anti-inflammatory or menopause treatment, respectively. The natural medicine line, including AYURSULIN and PROLIFE, caters to consumers seeking alternative treatments in diabetes and reproductive health. Revenue is derived from both B2B sales of APIs and direct B2C or B2B2C sales of branded formulations across multiple therapeutic categories. Bal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bal Pharma stock

Working Capital of Bal Pharma is -817.93 M INR in 2026.

Working Capital of Bal Pharma changed from 46.90 M INR to -817.93 M INR, representing a -1,843.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Working Capital Bal Pharma since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's Bal Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bal Pharma

All Key Metrics — Bal Pharma